Oruka Therapeutics Soars on Psoriasis Drug Data, Announces $500M Offering
Oruka Therapeutics shares surged after interim data showed its psoriasis drug ORKA-001 achieved 63.5% complete skin clearance. The company also announced a $500M public offering.
IPO
